DARA BioSciences, Inc (NASDAQ:DARA) shares moved up 1.10% in last trading session and ended the day at $0.88. DARA Gross Margin is 79.20% and its has a return on assets of -52.70%. DARA BioSciences, Inc (NASDAQ:DARA) quarterly performance is 12.83%. The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of DARA BioSciences, Inc. (NASDAQ:DARA) relating to the proposed buyout of the Company by Midatech Pharma PLC.

http://www.propertymentorgroup.com/...uticals-inc-nasdaqaqxp/1298920/

da jemand den richtigen gefunden , der bei den DaraStinkern  ermittelt

Brower Piven is the only firm headquartered in Maryland with a practice dedicated primarily to shareholder class action litigation.

http://www.businesswire.com/news/home/...-Based-Securities-Litigation  

fuer die klitsche  

vielleicht ergibt sich da was

http://money.cnn.com/news/newsfeeds/articles/...ire/11G055062-001.htm  

 
zwar schon älter....


DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush


http://www.darabio.com/media-center/press-releases?detail=652  

DARA Biosciences: An Attractive Short Term Merger Play


Nov. 30, 2015 2:32 PM ET |  About: DARA Biosciences, Inc. (DARA)



Disclosure: I am/we are long DARA. (More...)









Summary

•
DARA is planning to be acquired by UK-listed Midatech Pharma.
•
Midatech's offer to DARA shareholders consists of ADRs as well as a CVR based on certain milestones.
•
After the deal is completed Midatech's ADRs will start trading in the US.
•
Due to lack of institutional interest DARA trades at a 16% discount to Midatech's offer (excl. CVR).
•
DARA's shareholders will vote on this deal on Wednesday, making this an attractive short term play.